These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21985525)

  • 1. Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: a comparative study of subcutaneous and intranasal administration in mice.
    Hashem FM; Fahmy SA; El-Sayed AM; Al-Sawahli MM
    Pharm Dev Technol; 2013; 18(5):1175-85. PubMed ID: 21985525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An experimental divalent vaccine based on biodegradable microspheres induces protective immunity against tetanus and diphtheria.
    Peyre M; Sesardic D; Merkle HP; Gander B; Johansen P
    J Pharm Sci; 2003 May; 92(5):957-66. PubMed ID: 12712415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres.
    Jaganathan KS; Rao YU; Singh P; Prabakaran D; Gupta S; Jain A; Vyas SP
    Int J Pharm; 2005 Apr; 294(1-2):23-32. PubMed ID: 15814228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a diphtheria and tetanus PLGA microencapsulated vaccine formulation without stabilizers.
    Quintilio W; Takata CS; Sant'Anna OA; da Costa MH; Raw I
    Curr Drug Deliv; 2009 Jul; 6(3):297-04. PubMed ID: 19604144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid.
    Pirouzmand H; Khameneh B; Tafaghodi M
    Pharm Biol; 2017 Dec; 55(1):212-217. PubMed ID: 27927058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres.
    Gupta RK; Griffin P; Rivera R; Siber GR
    Dev Biol Stand; 1998; 92():277-87. PubMed ID: 9554282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice.
    Zurbriggen R; Glück R
    Vaccine; 1999 Mar; 17(11-12):1301-5. PubMed ID: 10195764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabrication of chitosan microspheres using vanillin/TPP dual crosslinkers for protein antigens encapsulation.
    Walke S; Srivastava G; Nikalje M; Doshi J; Kumar R; Ravetkar S; Doshi P
    Carbohydr Polym; 2015 Sep; 128():188-98. PubMed ID: 26005155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A long acting biodegradable controlled delivery of chitosan microspheres loaded with tetanus toxoide as model antigen.
    Varma S; Sadasivan C
    Biomed Pharmacother; 2014 Mar; 68(2):225-30. PubMed ID: 24051124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan-HPMC-blended microspheres as a vaccine carrier for the delivery of tetanus toxoid.
    Arthanari S; Mani G; Peng MM; Jang HT
    Artif Cells Nanomed Biotechnol; 2016; 44(2):517-23. PubMed ID: 25472756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal vaccination against plague, tetanus and diphtheria.
    Alpar HO; Eyles JE; Williamson ED; Somavarapu S
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):173-201. PubMed ID: 11516788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal booster vaccination against diphtheria and tetanus in man.
    Aggerbeck H; Gizurarson S; Wantzin J; Heron I
    Vaccine; 1997 Feb; 15(3):307-16. PubMed ID: 9139491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine.
    Singh M; Li XM; Wang H; McGee JP; Zamb T; Koff W; Wang CY; O'Hagan DT
    Infect Immun; 1997 May; 65(5):1716-21. PubMed ID: 9125552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the new reduced-dose tetanus-diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study.
    Han SB; Rhim JW; Shin HJ; Kim SY; Kim JH; Kim HH; Lee KY; Kim HM; Choi YY; Ma SH; Kim CS; Kim DH; Ahn DH; Kang JH
    J Microbiol Immunol Infect; 2017 Apr; 50(2):207-213. PubMed ID: 26055693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a single dose of diphtheria-tetanus toxoids among adults in Odessa, Ukraine, 1995: immunogenicity and adverse reactions.
    Golaz A; Hardy IR; Glushkevich TG; Areytchiuk EK; Deforest A; Strebel P; Wharton M; Sutter RW
    J Infect Dis; 2000 Feb; 181 Suppl 1():S203-7. PubMed ID: 10657215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvanticity of pGPL-Mc and LRS in the immune responses of monkeys to oral immunization with diphtheria and tetanus toxoids.
    Mirchamsy H; Neway T; Hamedi M; Pilet C
    Comp Immunol Microbiol Infect Dis; 1997 Jan; 20(1):13-20. PubMed ID: 9023036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunogenicity and safety of a tetanus-diphtheria vaccine (adult type): clinical trial in adults].
    Gil A; Dal-Ré R; González A; Lasheras L; Aguilar L; del Rey J
    Med Clin (Barc); 1995 Feb; 104(4):126-9. PubMed ID: 7898155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
    Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
    Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.